For years, tacrolimus has been extensively used by dermatologists around the world to treat atopic dermatitis, and in 2009 the treatment received approval from the European Medicines Agency (EMA) as maintenance treatment to prevent or delay flare-ups in adults and children with moderate-to-severe atopic dermatitis unresponsive to conventional topical corticosteroid therapy. This approval has been very well received by dermatology experts, such as José M. Mascaró, Professor Emeritus of Dermatology at the University of Barcelona, who recently noted that "dermatologists using tacrolimus are happy with the results, happy with the safety and now very happy because the EMA recognized that it is really safe." The safety profile and efficacy of tacrolimus has been ...